** Shares of Antengene Corp 6996.HK rise 5.6% to HK$5.84
** Stock at highest level since Feb 2023, set for sixth consecutive session of gains
** Innovative oncology medicines-focused clinical-stage biopharmaceutical group says its Xpovio approved in China for second-line treatment of multiple myeloma
** Hang Seng Biotech Index .HSHKBIO rises 2.6%, while benchmark Hang Seng Index .HSI falls 1.1%
** YTD, stock up 783%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.